ArticleNeuro-oncology advances

Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab.

Collin T Le et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.